A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
Latest Information Update: 24 May 2024
At a glance
- Drugs AZD-0466 (Primary) ; Voriconazole
- Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms NIMBLE
- Sponsors AstraZeneca; AstraZeneca AB
- 24 Aug 2023 Status changed from suspended to discontinued. Trial terminated based on benefit-risk profile assessment.
- 18 Aug 2023 This trial has been discontinued in Germany (End Date: 24 Jul 2023), according to European Clinical Trials Database record.
- 02 Aug 2023 Planned End Date changed from 17 Oct 2024 to 10 Aug 2023.